A recent study presented at the American Society of Hematology's 2025 Annual Meeting has shed light on a concerning disparity in survival rates for Black patients diagnosed with acute myeloid leukemia (AML). The findings, based on three decades of clinical trial data, reveal a stark contrast in outcomes between Black and White patients, leaving researchers and medical professionals searching for answers.
The Disparity in Survival Rates: A Troubling Reality
Lead study author, Dr. Shella Saint Fleur-Lominy, from the University of Maryland School of Medicine, suggests that the difference in survival rates may be attributed to various factors, including social determinants and potential unknown mutations. However, the study's focus on a patient population participating in large clinical trials suggests that social factors may not be the sole explanation.
Unraveling the Mystery: Genetic Factors and Beyond
The research team examined data from 10 ECOG-ACRIN phase 2 and 3 interventional clinical trials spanning from 1984 to 2019, involving 3469 White patients, 184 Black patients, and 156 patients of other ethnicities. Notably, Black patients were diagnosed at a younger age, with a median age of 47.9 years compared to 53.5 years for White patients. Despite this, the study found no significant difference in the prevalence of complex karyotype (CK) or other genetic abnormalities associated with AML between the two groups.
However, an intriguing finding emerged: Black patients with the NPM1 mutation, present in about 30% of individuals, experienced worse overall survival compared to White patients with the same mutation. This contradicts the usual association of NPM1 with a better response to treatment, raising questions about the impact of this mutation on Black patients.
The Need for Further Exploration: Uncovering the Full Picture
Dr. Bhavana Bhatnagar, a hematologist-oncologist familiar with the study, highlights the potential for more aggressive treatment approaches for Black patients with AML. She emphasizes the importance of recognizing that prognostic indicators based on predominantly White populations may not accurately reflect the reality for Black patients.
Saint Fleur-Lominy agrees, stating that more research is crucial to understanding the complex interplay of cytogenetics and other factors contributing to racial disparities in AML outcomes. She encourages clinicians to advise patients, especially Black patients, about the limitations of current prognostic studies in AML, emphasizing the need for a more comprehensive understanding of the disease.
As the medical community grapples with these findings, the question remains: How can we ensure equitable treatment and outcomes for all patients, regardless of race or ethnicity? Join the discussion and share your thoughts on this critical issue.
